Drug profile · INN
dasabuvir sodium
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium (VIEKIRA PAK (COPACKAGED)) is a rna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — dasabuvir sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
dasabuvir sodium (VIEKIRA PAK (COPACKAGED)) is a rna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
RNA-directed RNA polymerase inhibitor
Primary target: RNA-directed RNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is dasabuvir sodium?
dasabuvir sodium (VIEKIRA PAK (COPACKAGED)) is a rna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dasabuvir sodium?
VIEKIRA PAK (COPACKAGED) is a marketed brand name for dasabuvir sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dasabuvir sodium?
dasabuvir sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.